Tandem Diabetes Care Announces Director Changes and Shareholder Votes

TL;DR

Tandem Diabetes Care swapped a director and is holding shareholder votes.

AI Summary

Tandem Diabetes Care, Inc. announced on May 22, 2024, the departure of director Dr. Steven R. Smith and the election of Dr. Jennifer L. Schneider as a new director. The company also reported on compensatory arrangements for certain officers and submitted matters to a vote of security holders.

Why It Matters

Changes in board composition can signal shifts in company strategy or governance, while shareholder votes directly impact corporate decision-making.

Risk Assessment

Risk Level: low — The filing reports routine corporate governance changes and shareholder matters, which typically carry low immediate risk.

Key Players & Entities

• Tandem Diabetes Care, Inc. (company) — Registrant
• Dr. Steven R. Smith (person) — Departing Director
• Dr. Jennifer L. Schneider (person) — Newly Elected Director
• May 22, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — ich Registered Common Stock, par value $0.001 per share TNDM Nasdaq Global Market I

Filing Documents

• tndm-20240522.htm (8-K) — 54KB
• 0001438133-24-000118.txt ( ) — 177KB
• tndm-20240522.xsd (EX-101.SCH) — 2KB
• tndm-20240522_lab.xml (EX-101.LAB) — 21KB
• tndm-20240522_pre.xml (EX-101.PRE) — 12KB
• tndm-20240522_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders . On May 22, 2024, the Company held a virtual Annual Meeting of Stockholders (the "Annual Meeting"). There were 64,563,476 shares of the Company's common stock ("Common Stock") outstanding on March 25, 2024, the record date for the Annual Meeting. At the Annual Meeting, 54,562,542 shares of Common Stock were present virtually or represented by proxy. The following tables set forth the final results of the voting for the matters voted upon at the Annual Meeting. These matters are described in more detail in the Proxy Statement. Proposal 1 : To elect nine directors for a one-year term expiring at the 2025 annual meeting of stockholders. The stockholders elected nine directors by the following votes: Name of Director For Against Abstain Broker Non-Votes Rebecca Robertson 47,954,795 2,561,515 32,594 4,013,638 Dick Allen 45,909,796 4,617,309 21,799 4,013,638 Myoungil Cha 49,683,636 842,355 22,913 4,013,638 Peyton Howell 49,481,630 1,045,778 21,496 4,013,638 Joao Malagueira 50,040,471 484,790 23,643 4,013,638 Kathleen McGroddy-Goetz 48,668,928 1,846,379 33,597 4,013,638 John Sheridan 50,341,404 186,616 20,884 4,013,638 Rajwant Sodhi 48,933,345 1,594,611 20,948 4,013,638 Christopher Twomey 45,464,764 5,049,109 35,031 4,013,638 2 Proposal 2 : To approve the Company's 2013 Employee Stock Purchase Plan, as amended, to increase the number of shares authorized for issuance under the plan by 3,000,000 shares. This proposal was approved and the voting results were as follows: For Against Abstain Broker Non-Votes 50,419,028 117,501 12,375 4,013,638 Proposal 3 : To approve the Company's 2023 Long-Term Incentive Plan, as amended, to increase the number of shares authorized for issuance under the plan by 3,000,000 shares. This proposal was approved and the voting results were as follows: For Against Abstain Broker Non-Votes 47,565,578 2,958,516 24,810 4,013,638 Proposal 4 : To approve, on a n

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Tandem Diabetes Care, Inc. By: /s/ SHANNON M. HANSEN Shannon M. Hansen Executive Vice President, Chief Legal, Privacy & Compliance Officer and Secretary Date: May 23, 2024 4

View Full Filing

View this 8-K filing on SEC EDGAR